Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study

International Journal of Cancer

Volumn 142, Issue 7, 2018, Pages 1480-1489

  Babaei, Masoud ^a   Balavarca, Yesilda ^a   Jansen, Lina ^a   Lemmens, Valery ^b,c   van Erning, Felice N ^b,c   van Eycken, Liesbet ^d   Vaes, Evelien ^d   Sjövall, Annika ^e   Glimelius, Bengt ^f   Ulrich, Cornelia M ^a,g   Schrotz King, Petra ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Netherlands Comprehensive Cancer Organization   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Belgian Cancer Registry   (Belgium)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g UNIVERSITY OF UTAH   (United States)

Author keywords

adjuvant chemotherapy; colon cancer; survival; variations

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; AGING; ARTICLE; BELGIUM; CANCER MORTALITY; CANCER STAGING; COLON CANCER; COLON RESECTION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; VERY ELDERLY; CAUCASIAN; CLINICAL TRIAL; COLON TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTILIZATION;

ANTINEOPLASTIC AGENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME;

EID: 85037351592     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.31168     Document Type: Article

References (39)

1. Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27–32.
2. Pahlman LA, Hohenberger WM, Matzel K, et al. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated? J Clin Oncol 2016;34:1297–9.
3. Bernhoff R, Martling A, Sjovall A, et al. Improved survival after an educational project on colon cancer management in the county of Stockholm–A population based cohort study. Eur J Surg Oncol 2015;41:1479–84.
4. Bertelsen CA, Neuenschwander AU, Jansen JE, et al. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. Lancet Oncol 2015;16:161–8.
5. Deijen CL, Vasmel JE, de Lange-de Klerk ESM, et al. Ten-year outcomes of a randomised trial of laparoscopic versus open surgery for colon cancer. Surg Endosc 2017;31:2607–15.
6. Bockelman C, Engelmann BE, Kaprio T, et al. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 2015;54:5–16.
7. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479–516.
8. Winget M, Hossain S, Yasui Y, et al. Characteristics of patients with stage iii colon adenocarcinoma who fail to receive guideline-recommended treatment. Cancer Am Cancer Soc. 2010;116:4849–56.
9. Hines RB, Bimali M, Johnson AM, et al. Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort. Cancer Epidemiol 2016;44:77–83.
10. Dobie SA, Baldwin LM, Dominitz JA, et al. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006;98:610–9.
11. Morris M, Platell C, McCaul K, et al. Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis 2007;22:887–95.
12. Benson AB. 3rd,. New approaches to the adjuvant therapy of colon cancer. Oncologist 2006;11:973–80.
13. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011;29:3381–8.
14. Benson AB, 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. JCO. 2004;22:3408–19.
15. Srivastava G, Renfro LA, Behrens RJ, et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist 2014;19:492–7.
16. Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer Am Cancer Soc 2015;121:527–34.
17. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi64–72.
18. McVie G, Ringborg U. EurocanPlatform, an FP7 project of the European Commission-first year commentary. Ecancermedicalscience 2012;6:ed13
19. Babaei M, Balavarca Y, Jansen L, et al. Minimally invasive colorectal cancer surgery in Europe implementation and outcomes. Medicine 2016;95:e3812.
20. Ratto C, Ricci R. Potential pitfalls concerning colorectal cancer classification in the seventh edition of the AJCC Cancer Staging Manual. Dis Colon Rectum 2011;54:E232–E.
21. Netherlands Comprehensive Cancer Centre. National Evidence Based Guideline for Colon Cancer, 2014. Available from .
22. Mi XJ, Hammill BG, Curtis LH, et al. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Statist Med. 2016;35:4824–36.
23. Breugom AJ, Bastiaannet E, Boelens PG, et al. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. Eur J Cancer 2016;63:110–7.
24. Peeters M, Zlotta A, Roucoux F, et al. Nationale Richtlijnen van het College voor oncologie Reports vol. 29A. Brussel: FederaalKenniscentrum voor de gezondheidszorg (KCE); April 2006. KCERef. D/2006/10.273/12.
25. Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 2010;10:S115–29.
26. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490–502.
27. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. JCO. 2015;33:1787–96.
28. Pasetto LM, Rossi E, Jirillo A, et al. Colorectal cancer adjuvant treatment in elderly patients. Crit Rev Oncol Hematol 2005;55:201–6.
29. El Shayeb M, Scarfe A, Yasui Y, et al. Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review. BMC Res Notes 2012;5:269
30. Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. JCO. 2012;30:3353–60.
31. Hendlisz A, Puleo F, Deleporte A, et al. In deciphering the future of adjuvant treatment in colon cancer, the journey matters more than the achievements. Curr Colorectal Cancer Rep 2016;12:57–66.
32. Meyers BM, Al-Shamsi HO, Figueredo AT. Cochrane systematic review and meta-analysis of adjuvant therapy for stage II colon cancer ASCO Annual Meeting Proceedings 2015; 33:3513.
33. Booth CM, Nanji S, Wei X, et al. Adjuvant chemotherapy for stage II colon cancer: practice patterns and effectiveness in the general population. Clin Oncol 2017;29:e29–38.
34. Casadaban L, Rauscher G, Aklilu M, et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer Am Cancer Soc 2016;122:3277–87.
35. Hippisley-Cox J, Coupland C. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. BMJ 2017;357:j2497.
36. Verhoeff SR, van Erning FN, Lemmens VE, et al. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 2016;139:187–93.
37. Ostenfeld EB, Norgaard M, Thomsen RW, et al. Comorbidity and survival of Danish patients with colon and rectal cancer from 2000–2011: a population-based cohort study. Clin Epidemiol 2013;5:65–74.
38. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer 2009;9:116
39. Hsiao FY, Mullins CD, Onukwugha E, et al. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a “real world” analysis using Surveillance, Epidemiology, and End Results-Medicare data. J Am Geriatr Soc 2011;59:1717–23.